Accent Microcell IPO GMP, Details, Date, Price, Allotment 2023

Accent Microcell  IPO description – Accent Microcell   India Limited is coming up with its Initial public offering. The IPO will be open for subscription on December 08, 2023



Accent Microcell IPO – Details


IPO Open Date 08 December 2023
IPO Close Date 12 December 2023
Issue Type Book Built Issue IPO
Issue Size 56,00,000 Shares Worth ₹78.40 Crore

Fresh Issue: 56,00,000 Shares Worth ₹78.40 Crore

Face Value ₹10 per equity share
IPO Price ₹133 – ₹140
Market Lot 1000 Shares
Minimum Order 1000 Shares (1 Lot)
Listing At NSE SME
Register Kfin Technologies Limited
Retail Shares Offered 35%
NII (HNI) Shares Offered 15%
Other Shares Offered 50%



Accent Microcell IPO – Date Schedule


IPO Opening Date 08 December 2023
IPO Closing Date 11 December 2023
Finalization of Basis of Allotment 13 December 2023
Refunds Initiation 14 December 2023
Transfer of shares to demat accounts 14 December 2023
Listing Date of IPO 15 December 2023


Accent Microcell IPO – About Company 


Accent Microcell Limited produces high-quality cellulose-based excipients mainly for the Pharmaceutical, Nutraceutical, Food, Cosmetic and other industries. The Company has carved a niche in producing high-quality cellulose-based excipients, that meet international quality standards. The company operates two state-of-the-art manufacturing facilities at Pirana Road in Ahmedabad and Dahej SEZ in Bharuch.

These facilities have enabled the development of a robust global sales model, serving customers across India and in more than 45 countries worldwide, including the USA, Canada, Germany, UK, Japan, China, Australia, Korea, Netherlands, Turkey, Vietnam, Italy, Indonesia, Poland, Egypt, France, Thailand, New Zealand, Brazil, Russia, Mexico, Chile, Zimbabwe, Denmark, and Greece.

The company specializes in the manufacture of Microcrystalline Cellulose (“MCC”), which is an odourless, fine white powder, a purified form of cellulose that’s derived from the refinement of highly purified wood pulp. It is widely used as a texturizer, anticaking agent, binder, lubricant, bulking agent, and diluent, and finds a wide range of applications in Pharmaceutical, Nutraceutical, Food, Cosmetic and other industries.

The company manufactures 22 grades of MCC, with particle sizes ranging from 20 microns to 180 microns. The major grades of MCC manufactured and marketed by the Company are branded “accel“. Besides “accel“, the company also sells products under the names “acrocell“, “maccel“, and “Vincel“.


Accent Microcell IPO – Details
Accent Microcell IPO – Details


Accent Microcell IPO – Industry Overview 


Pharmaceuticals Market size was valued at USD 209.85 billion in 2021 and is poised to grow from USD 222.4 billion in 2022 to USD 352.98 billion by 2030, growing at a CAGR of 5.9% in the forecast period (2023-2030). 

The global microcrystalline cellulose (mcc) market was valued at $401.1 million in 2021, and is projected to reach $712.9 million by 2031, growing at a CAGR of 5.9% from 2022 to 2031. 

India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving over time into a thriving industry growing at a CAGR of 9.43% since the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has themost number of pharmaceutical manufacturing facilities that are in compliance with the US Food and Drug Administration (USFDA) and has 500 API producers that make for around 8% of the worldwide API market.

Market size of India pharmaceuticals industry is expected to reach US$ 65 billion by 2024, and ~US$ 130 billion by 2030. According to the government data, the Indian pharmaceutical industry is worth approximately US$ 50 billion with over US$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India.

India is among the top 12 destinations for biotechnology worldwide and 3rd largest destination for biotechnology in Asia Pacific. In 2022, India’s Biotechnology industry has crossed US$ 80.12 billion, growing 14% from the previous year. The Indian pharmaceutical industry has seen a massive expansion over the last few years and is expected to reach about 13% of the size of the global pharma market while enhancing its quality, affordability, and innovation.


Accent Microcell IPO – Financial Performance


FY 2022 FY 2023 Q1 FY 2024
Revenue 165.71 204.19 58.81
Expenses 159.95 191.48 51.65
Net income 5.89 13.01 7.06

Figures in INR Crores


Accent Microcell IPO – Valuations & Margins


FY 2021 FY 2022 FY 2023
EPS 3.72 4.57 10.06
PE ratio 13.22 – 13.92
RONW (%) 18.04 18.36 29.44
ROE (%) 19.00 20.07 34.11
NAV 61.92 74.21 34.19
EBITDA (%) 9.76 8.93 10.85
Debt/Equity 1.15 0.75 0.52


Accent Microcell IPO – Prospectus



Accent Microcell IPO – Competitive Strengths


  • Expansion in domestic & overseas market (Geographic Diversification): 
  • One of the leading manufacturers of MCC (cellulose based excipient) with over a decade experience. 
  • Strategically located manufacturing facilities.  
  • Government Incentives
  • Strong supplier base for sourcing of raw materials/ products 
  • Robust Quality and Service Standards 
  • Quality Certifications 


Accent Microcell IPO – Object Of The Issue


  • To Set up a plant at Navagam Kheda for manufacturing Croscarmellose Sodium (“CCS”), Sodium Starch Glycolate and Carboxymethylcellulose (CMC); and
  • General Corporate Purpose.


Accent Microcell IPO – Allotment Status

Accent Microcell IPO allotment status will be available on the KFin Tech website. Click on this link to get allotment status.

Accent Microcell IPO – Lots Size & Price


Application Lots Shares Amount ( Cut-Off)
Retail (Min) 1 1000 1,40,000
Retail (Max) 1 1000 1,40,000
HNI (Min) 2 2000 2,80,000

2023-10-13 (4)




Disclaimer – The content presented here is intended solely for analytical and educational purposes. If you consider investing, it is strongly advised to conduct your own thorough research. We do not endorse or recommend any specific stocks or initial public offerings (IPOs).


Leave a Comment